Elanco Animal Health Incorporated $ELAN Holdings Raised by Channing Capital Management LLC

Key Points

• Channing Capital Management LLC has increased its holdings in Elanco Animal Health by 11.7%, acquiring an additional 85,358 shares for a total of 817,127 shares valued at approximately $8.58 million.
• Analysts have raised their price targets for Elanco, with Piper Sandler setting a new target at $18.00 and UBS Group increasing theirs to $19.00, highlighting a consensus shift toward a Moderate Buy rating.
• Elanco Animal Health reported Q2 earnings of $0.26 EPS, exceeding expectations, with a year-over-year revenue growth of 4.8% and total revenue of $1.24 billion.

Channing Capital Management LLC boosted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 11.7% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 817,127 shares of the company's stock after buying an additional 85,358 shares during the period. Channing Capital Management LLC owned approximately 0.16% of Elanco Animal Health worth $8,580,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its stake in shares of Elanco Animal Health by 53.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 211,904 shares of the company's stock valued at $2,566,000 after acquiring an additional 73,838 shares during the period. Invesco Ltd. increased its holdings in Elanco Animal Health by 10.6% in the 4th quarter. Invesco Ltd. now owns 536,391 shares of the company's stock valued at $6,496,000 after purchasing an additional 51,233 shares in the last quarter. Mariner LLC increased its holdings in Elanco Animal Health by 79.6% in the 4th quarter. Mariner LLC now owns 56,193 shares of the company's stock valued at $680,000 after purchasing an additional 24,901 shares in the last quarter. Freedom Investment Management Inc. raised its position in Elanco Animal Health by 9.1% in the fourth quarter. Freedom Investment Management Inc. now owns 20,746 shares of the company's stock valued at $251,000 after purchasing an additional 1,725 shares during the period. Finally, Forum Financial Management LP lifted its stake in shares of Elanco Animal Health by 22.7% during the fourth quarter. Forum Financial Management LP now owns 16,068 shares of the company's stock worth $195,000 after purchasing an additional 2,977 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Up 2.3%

Shares of Elanco Animal Health stock traded up $0.4030 on Friday, hitting $17.8930. 6,722,648 shares of the company's stock traded hands, compared to its average volume of 6,561,933. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $18.08. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The stock has a market cap of $8.89 billion, a P/E ratio of 20.81, a PEG ratio of 3.32 and a beta of 1.66. The firm's 50-day moving average is $15.08 and its 200 day moving average is $12.47.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the previous year, the firm earned $0.30 earnings per share. The business's revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stifel Nicolaus raised their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. UBS Group increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, August 8th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Piper Sandler raised their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, August 11th. Finally, Zacks Research lowered shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of "Moderate Buy" and a consensus target price of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.